pharma · Vitiligo · Erythropoietic Protoporphyria (EPP)
CLINUVEL PHARMACEUTICALS
Clinuvel Europe Limited
CLINUVEL PHARMACEUTICALS clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2001
- Employees
- 83
- Programs
- 5
- Drugs
- 3
- Patents
- 0
CLINUVEL PHARMACEUTICALS projects
5 ClinicalTrials.gov programs sponsored by CLINUVEL PHARMACEUTICALS.
CLINUVEL PHARMACEUTICALS has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SCENESSE 16 mg implant
Clinuvel Europe Limited
Vitiligo
1 trial -
PRENUMBRA
Clinuvel Europe Limited
Healthy volunteers
1 trial -
PRENUMBRA
Clinuvel Europe Limited
Arterial Ischaemic Stroke (AIS)
1 trial -
PRENUMBRA
Clinuvel Europe Limited
Parkinson's Disease
1 trial -
SCENESSE 16 mg implant
Clinuvel Europe Limited
Erythropoietic Protoporphyria (EPP)
1 trial
Frequently asked questions
How many clinical projects does CLINUVEL PHARMACEUTICALS have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.